This pipeline uses various statistical tests to identify genes whose promoter methylation levels correlated to selected clinical features.
Testing the association between 17320 genes and 8 clinical features across 530 samples, statistically thresholded by Q value < 0.05, 7 clinical features related to at least one genes.
-
1 gene correlated to 'Time to Death'.
-
CDC73
-
139 genes correlated to 'AGE'.
-
KIF15 , MEX3C , EGR2 , LGALS8 , RPL13A , ...
-
186 genes correlated to 'GENDER'.
-
ALDOC , ZNF486 , CRIP1 , DNAJC15 , NMNAT3 , ...
-
161 genes correlated to 'RADIATIONS.RADIATION.REGIMENINDICATION'.
-
CCDC86 , NDUFB4 , TUBA4B , HS1BP3 , MAP3K10 , ...
-
6 genes correlated to 'DISTANT.METASTASIS'.
-
NHEDC1 , IL10RB , C9ORF153 , TINF2 , SNX29 , ...
-
39 genes correlated to 'LYMPH.NODE.METASTASIS'.
-
SS18L1 , ZNF235 , MANBAL , HCRTR2 , TMEM33 , ...
-
31 genes correlated to 'NEOPLASM.DISEASESTAGE'.
-
IDH3B , DRG2 , ATP5J , HIST1H4C , WDR74 , ...
-
No genes correlated to 'NUMBER.OF.LYMPH.NODES'
Complete statistical result table is provided in Supplement Table 1
Clinical feature | Statistical test | Significant genes | Associated with | Associated with | ||
---|---|---|---|---|---|---|
Time to Death | Cox regression test | N=1 | shorter survival | N=0 | longer survival | N=1 |
AGE | Spearman correlation test | N=139 | older | N=126 | younger | N=13 |
GENDER | t test | N=186 | male | N=41 | female | N=145 |
RADIATIONS RADIATION REGIMENINDICATION | t test | N=161 | yes | N=139 | no | N=22 |
DISTANT METASTASIS | ANOVA test | N=6 | ||||
LYMPH NODE METASTASIS | ANOVA test | N=39 | ||||
NUMBER OF LYMPH NODES | Spearman correlation test | N=0 | ||||
NEOPLASM DISEASESTAGE | ANOVA test | N=31 |
Time to Death | Duration (Months) | 0-223.4 (median=17.9) |
censored | N = 444 | |
death | N = 58 | |
Significant markers | N = 1 | |
associated with shorter survival | 0 | |
associated with longer survival | 1 |
HazardRatio | Wald_P | Q | C_index | |
---|---|---|---|---|
CDC73 | 0 | 1.388e-06 | 0.024 | 0.355 |
AGE | Mean (SD) | 57.6 (13) |
Significant markers | N = 139 | |
pos. correlated | 126 | |
neg. correlated | 13 |
SpearmanCorr | corrP | Q | |
---|---|---|---|
KIF15 | 0.3146 | 1.281e-13 | 2.22e-09 |
MEX3C | 0.2866 | 1.839e-11 | 3.19e-07 |
EGR2 | 0.2857 | 2.157e-11 | 3.74e-07 |
LGALS8 | -0.2825 | 3.667e-11 | 6.35e-07 |
RPL13A | 0.281 | 4.709e-11 | 8.15e-07 |
C10ORF35 | 0.2783 | 7.276e-11 | 1.26e-06 |
FASN | 0.2741 | 1.43e-10 | 2.48e-06 |
RPL27A | 0.2672 | 4.222e-10 | 7.31e-06 |
RPL7A | 0.2661 | 5.029e-10 | 8.71e-06 |
EIF4A1 | 0.2625 | 8.783e-10 | 1.52e-05 |
GENDER | Labels | N |
FEMALE | 524 | |
MALE | 6 | |
Significant markers | N = 186 | |
Higher in MALE | 41 | |
Higher in FEMALE | 145 |
T(pos if higher in 'MALE') | ttestP | Q | AUC | |
---|---|---|---|---|
ALDOC | -25.69 | 1.408e-93 | 2.44e-89 | 0.8677 |
ZNF486 | -18.27 | 5.628e-58 | 9.75e-54 | 0.8165 |
CRIP1 | -16.92 | 1.283e-51 | 2.22e-47 | 0.8728 |
DNAJC15 | -13.77 | 1.089e-35 | 1.89e-31 | 0.7325 |
NMNAT3 | -13.22 | 4.298e-34 | 7.44e-30 | 0.6905 |
LOC400043 | -13.13 | 3.755e-31 | 6.5e-27 | 0.6023 |
RND2 | -13.17 | 2.007e-28 | 3.48e-24 | 0.792 |
EML1 | -11.43 | 5.825e-27 | 1.01e-22 | 0.6072 |
SPC25 | -12.2 | 3.114e-26 | 5.39e-22 | 0.7516 |
HSPC157 | -12.95 | 7.35e-25 | 1.27e-20 | 0.6307 |
161 genes related to 'RADIATIONS.RADIATION.REGIMENINDICATION'.
RADIATIONS.RADIATION.REGIMENINDICATION | Labels | N |
NO | 141 | |
YES | 389 | |
Significant markers | N = 161 | |
Higher in YES | 139 | |
Higher in NO | 22 |
T(pos if higher in 'YES') | ttestP | Q | AUC | |
---|---|---|---|---|
CCDC86 | 6.9 | 3.016e-11 | 5.22e-07 | 0.6798 |
NDUFB4 | 6.53 | 2.722e-10 | 4.71e-06 | 0.6671 |
TUBA4B | 6.4 | 4.162e-10 | 7.21e-06 | 0.6405 |
HS1BP3 | 6.25 | 1.179e-09 | 2.04e-05 | 0.6597 |
MAP3K10 | 6.24 | 1.408e-09 | 2.44e-05 | 0.6496 |
PTRH1 | 6.12 | 1.798e-09 | 3.11e-05 | 0.6147 |
TICAM1 | 6.16 | 2.361e-09 | 4.09e-05 | 0.661 |
DDX54 | 6.12 | 2.798e-09 | 4.84e-05 | 0.6528 |
RASL11A | 6.06 | 2.853e-09 | 4.94e-05 | 0.6322 |
CCDC85B | 6.08 | 3.693e-09 | 6.39e-05 | 0.661 |
DISTANT.METASTASIS | Labels | N |
CM0 (I+) | 1 | |
M0 | 418 | |
M1 | 3 | |
MX | 62 | |
Significant markers | N = 6 |
ANOVA_P | Q | |
---|---|---|
NHEDC1 | 1.503e-28 | 2.6e-24 |
IL10RB | 7.967e-12 | 1.38e-07 |
C9ORF153 | 1.715e-08 | 0.000297 |
TINF2 | 3.257e-07 | 0.00564 |
SNX29 | 5.012e-07 | 0.00868 |
DNAJB7 | 2.47e-06 | 0.0428 |
LYMPH.NODE.METASTASIS | Labels | N |
N0 | 139 | |
N0 (I+) | 11 | |
N0 (I-) | 60 | |
N0 (MOL+) | 1 | |
N1 | 61 | |
N1A | 76 | |
N1B | 22 | |
N1C | 2 | |
N1MI | 13 | |
N2 | 33 | |
N2A | 35 | |
N3 | 8 | |
N3A | 16 | |
N3B | 1 | |
NX | 6 | |
Significant markers | N = 39 |
ANOVA_P | Q | |
---|---|---|
SS18L1 | 1.514e-67 | 2.62e-63 |
ZNF235 | 1.125e-47 | 1.95e-43 |
MANBAL | 1.686e-31 | 2.92e-27 |
HCRTR2 | 7.914e-23 | 1.37e-18 |
TMEM33 | 4.957e-19 | 8.58e-15 |
ZNF33A | 3.578e-17 | 6.2e-13 |
SCRN2 | 1.593e-14 | 2.76e-10 |
KCNQ5 | 6.81e-13 | 1.18e-08 |
CLPP | 4.655e-11 | 8.06e-07 |
TMEM208 | 1.445e-10 | 2.5e-06 |
NUMBER.OF.LYMPH.NODES | Mean (SD) | 2.41 (4.5) |
Significant markers | N = 0 |
NEOPLASM.DISEASESTAGE | Labels | N |
STAGE I | 43 | |
STAGE IA | 34 | |
STAGE IB | 2 | |
STAGE II | 8 | |
STAGE IIA | 160 | |
STAGE IIB | 114 | |
STAGE III | 2 | |
STAGE IIIA | 78 | |
STAGE IIIB | 12 | |
STAGE IIIC | 23 | |
STAGE IV | 3 | |
STAGE X | 4 | |
Significant markers | N = 31 |
-
Expresson data file = BRCA-TP.meth.for_correlation.filtered_data.txt
-
Clinical data file = BRCA-TP.clin.merged.picked.txt
-
Number of patients = 530
-
Number of genes = 17320
-
Number of clinical features = 8
For survival clinical features, Wald's test in univariate Cox regression analysis with proportional hazards model (Andersen and Gill 1982) was used to estimate the P values using the 'coxph' function in R. Kaplan-Meier survival curves were plot using the four quartile subgroups of patients based on expression levels
For continuous numerical clinical features, Spearman's rank correlation coefficients (Spearman 1904) and two-tailed P values were estimated using 'cor.test' function in R
For two-class clinical features, two-tailed Student's t test with unequal variance (Lehmann and Romano 2005) was applied to compare the log2-expression levels between the two clinical classes using 't.test' function in R
For multi-class clinical features (ordinal or nominal), one-way analysis of variance (Howell 2002) was applied to compare the log2-expression levels between different clinical classes using 'anova' function in R
For multiple hypothesis correction, Q value is the False Discovery Rate (FDR) analogue of the P value (Benjamini and Hochberg 1995), defined as the minimum FDR at which the test may be called significant. We used the 'Benjamini and Hochberg' method of 'p.adjust' function in R to convert P values into Q values.
This is an experimental feature. The full results of the analysis summarized in this report can be downloaded from the TCGA Data Coordination Center.